Table 5.
Various types of targeted drug delivery systems for CSC therapy and their potential applications.
| Sr. no. | CSCs source and marker | Ligand/Receptor | Therapeutic agents and drug delivery system | References | |
|---|---|---|---|---|---|
| 1. | Breast cancer, MDA-MB-231 cells, CD133+ | Anti-CD133 antibody/CD133 | Paclitaxel | Nanoparticles formulated using PLGA polymer | Swaminathan et al., 2013 |
| 2. | Non-small cell lung cancer, A549 cells, CD44+ | Hyaluronic acid/CD44 | SSB/PLK1 siRNA | HA-PEI/PEG nanosystems | Ganesh et al., 2013 |
| 3. | Breast cancer, MCF-7 cells, CD44+ | Chitosan/CD44 | Doxorubicin | Pluronic F127-Chitosan nanoparticles | Rao et al., 2015 |
| 4. | Hepatocellular carcinoma, HepG2 cells, CD44+ | Anti-CD44 antibody/CD44 | Doxorubicin | Liposomal nanoparticle | Wang L. et al., 2012 |
| 5. | Colorectal cancer, etc., HT-29 cells, etc., CD133+ | Transferrin/transferrin receptor | wtp53 gene | Liposomal delivery complex | Kim et al., 2014b |
| 6. | Glioblastoma, N08-74 cells, etc., CD133+ | Cetuximab/epidermal growth factor (EGFR) | Cetuximab | Multifunctional magnetic iron-oxide nanoparticles (IONPs) | Kaluzova et al., 2015 |